• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Eli Lilly

Eli Lilly

Eli Lilly and Co LLY 2 Star

Last Price$78.90Day Change (%)3.26%
Open Price$76.15Day Change ($)2.49
Day Range76.02–79.5552-Week Range58.50–79.55

As of Fri 5/29/2015 7:05:00 PM | USD

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Fitch Rates Eli Lilly's Euro Notes Offering 'A'; Outlook Stable

    Fitch Rates Eli Lilly's Euro Notes Offering 'A'; Outlook Stable

  2. New Push Ties Cost of Drugs to How Well They Work

    New Push Ties Cost of Drugs to How Well They Work

  3. Merus Labs Appoints Frank Rotmann VP & Head of European Operations

    Merus Labs Appoints Frank Rotmann VP & Head of European Operations

  4. Research and Markets: Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020

    Research and Markets: Peptide Therapeutics Market (by Applications, by Route of Administration, and by Marketing Status) - Global Industry Analysis 2014 - 2020

  5. Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx

    Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech to Jointly Acquire U.S. Innovative Biotechnology Company Ambrx

  6. Research and Markets: Global Anal Cancer Pipeline Report 2015 - 6 Companies & 6 Drug Profiles

    Research and Markets: Global Anal Cancer Pipeline Report 2015 - 6 Companies & 6 Drug Profiles

  7. Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies

    Lilly and BioNTech Announce Research Collaboration on Novel Cancer Immunotherapies

  8. Research and Markets: Cognitive Impairment - Pipeline Review, H1 2015

    Research and Markets: Cognitive Impairment - Pipeline Review, H1 2015

  9. Research and Markets: Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025

    Research and Markets: Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025

  10. Egalet President and Chief Executive Officer Bob Radie Appointed to Pennsylvania Bio Board of Directors

    Egalet President and Chief Executive Officer Bob Radie Appointed to Pennsylvania Bio Board of Directors

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.